Shushan Hovsepyan: Can we change the game for sarcoma patients with immunotherapy?
Shushan Hovsepyan shared on LinkedIn:
“Can we change the game for sarcoma patients with immunotherapy?
Two days ago, The Lancet published a paper on the SU2C-SARC032 trial, testing pembrolizumab alongside standard radiotherapy and surgery for high-risk, stage III soft tissue sarcoma of the extremity.
Study arms:
1. Control: Radiotherapy + surgery
2. Experimental: Pembrolizumab + radiotherapy + surgery + adjuvant pembrolizumab
Key Results:
DFS: A 15% increase in 2-year survival in the pembro group (67% vs. 52%).
Targeted Benefit: Effective for high-grade, undifferentiated sarcoma.
With promising survival improvements and fewer toxic effects compared to traditional chemotherapy, immunotherapy could reshape treatment options for high-risk sarcoma patients.
With better survival rates and fewer side effects than traditional chemo, immunotherapy could change the approach for high-risk sarcoma patients.”
Authors: Yvonne M Mowery, Prof Karla V Ballman, Angela M Hong, Prof Scott M Schuetze, Andrew J Wagner, Varun Monga, Rachel S Heise, Steven Attia, Edwin Choy, Melissa A Burgess, Susie Bae, David I Pryor, Prof Brian A Van Tine, Gabriel Tinoco, Prof Bartosz Chmielowski, Prof Carolyn Freeman, Prof Alessandro Gronchi, Christian F Meyer, Mark A Dickson, Prof Lee Hartner, Lara E Davis, Benjamin C Powers, Everett J Moding, Prof Kent J Weinhold, Prof Matt van de Rijn, Prof Brian E Brigman, Richard F Riedel,
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023